Stay updated with breaking news from Leland Gershell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Oppenheimer & Co. Inc. (Oppenheimer) — a leading investment bank, wealth manager and a subsidiary of Oppenheimer Holdings (NYSE: OPY) — today...
Investor interest in newly-issued biotech stocks has been moribund for years, but the sector’s first IPO of 2024, CG Oncology, suggests that investors might...
Operator: Good morning, ladies and gentlemen, and thank you for standing by, and welcome to the UroGen Pharma Q3 2023 Earnings Call. Please be advised that today's conference is being recorded.
Approval Likely in U.S., EU for New Drug for Prader-Willi
After a shaky August for the markets, we have now entered the year’s final third and the bad news is that, going by the history books, September represents the market’s worst month of the year. The good news, however, is that according to Oppenheimer’s head of technical analysis, Ari Wald, any anticipated lull will be short-lived. “The key takeaway in our work is that, whether or not the advance is resuming imminently, it should only be a matter of time,” Wald recently said. “The Russell 2000’s